Question
Does the combination of baricitinib and remdesivir improve outcomes in patients hospitalized with COVID-19?
Conclusion
For hospitalized patients with COVID-19 and evidence of lower respiratory tract infection, the combination of baracitinib plus remdesivir results in faster time to recovery, especially in patients who require noninvasive mechanical ventilation or high-flow oxygen. No survival benefit is seen with this combination.
Recent Posts
- Surgery is no better than nonoperative treatment for Achilles tendon rupture in adults
- Another study fails to find PRP injections effective for adults with degenerative joint disease of the knee
- Short-term benefit from ultrasonography-guided steroid injection for Achilles tendinopathy
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Is there an association between gastric cancer and the use of proton pump inhibitors?
Leave A Comment